Media-no-image

A new European Consortium to improve therapeutic guidance for patients with metastatic breast cancer

Press Releases   •   Dec 04, 2013 09:39 EST

The CareMore* Consortium is a collaborative effort to advance diagnostic systems for therapy guidance in patients with metastatic breast cancer. The consortium associates five European partners from both academia and industry, and launches with a € 5M grant via the European Commission´s 7th Framework Program (FP7**).

Today's treatment of metastatic breast cancer is guided by characterisation of the primary tumour, while 90% of deaths due to breast cancer occur as a consequence of metastases. In up to 50% of all breast cancer patients the molecular profile of the metastasis is different from the primary tumour that is currently guiding treatment. The CareMore project will develop and clinically validate a system to guide treatment decisions in women with metastatic breast cancer based on molecular characterization of circulating tumour cells (CTCs), used as proxies for the metastatic tumour. 

Two unique methods will be combined, single cell-based in situ detection of genetic mutations and protein expression and improved CTC sampling and identification, provided by the participating small and medium sized enterprises (SMEs) Olink Bioscience and CytoTrack. Together with leading academic scientists at Erasmus MC Cancer Institute and Stockholm University and Philips, a strong industrial partner and leader in diagnostic imaging, the consortium aims to establish the clinical utility of the proposed approach.

"We are very pleased to have gathered such a strong team.” said Dr. Mats Gullberg, project coordinator for CareMore and Chief Technology Officer at Olink Bioscience. "The project offers a tremendous opportunity to advance our current ability to choose the correct treatment for each individual patient. While we anticipate heavy competition from standard immuno-staining methods we see a distinct competitive advantage in scoring genetic parameters in the same cell simultaneously. In view of the evident need of visual inspection for CTC identification, our proposed in situ molecular characterization assay has the potential to provide the most robust and cost effective approach for companion diagnostic based on CTCs."

A successful outcome of the CareMore project approach is expected to be readily replicated to other cancer types in which molecular classification is used for therapy guidance.

Consortium members
The project will be coordinated by Olink Bioscience (Sweden) with partners from the Netherlands, Denmark and Sweden. The CareMore Consortium unites researchers from two SME’s, two universities and one large industry. 

CareMore is a three-year project running from the 1st of September 2013 until the 30th of August 2016 and is funded by the 7th Framework Program of the European Commission. In addition to the research activities, CareMore will be organizing meetings, workshops and will be present at a number of international conferences.

Members of the consortium:

  • Olink Bioscience (Coordinator, SME), Mats Gullberg, SE
  • CytoTrack , Tom Hede Markussen, DK
  • Erasmus MC Cancer Institute, Stefan Sleijfer, NL
  • Philips Electronics Nederland B.V. Reinhold Wimberger-Friedl, NL
  • Stockholms Universitet, Mats Nilsson, SE

Contact
Dr. Mats Gullberg: +46-70-9428520, Mats.Gullberg@olink.com 
Dr. Ida Grundberg: +46-18-4443994, Ida.Grundberg@olink.com
CareMore website: www.CareMoreCTC.eu

* CareMore is the acronym to the project´s full title “Cancer Responsiveness Monitoring based on Resistance mutations in CTCs”.

** FP7 is the short name for the Seventh Framework Programme for Research and Technological Development. This is the EU's main instrument for funding research in Europe and it will run from 2007-2013.

The CareMore* Consortium is a collaborative effort to advance diagnostic systems for therapy guidance in patients with metastatic breast cancer. The consortium associates five European partners from both academia and industry, and launches with a € 5M grant via the European Commission´s 7th Framework Program (FP7**).

Read more »
Media-no-image

Olink Bioscience introduces a 92 protein biomarker panel for cardiovascular disease

Press Releases   •   Oct 29, 2013 08:57 EDT

Uppsala, Sweden, October 29, 2013 – Olink Bioscience today launches Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease. This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Cardiovascular disease is the number one cause of death worldwide and a growing health problem that requires massive medical intervention each year. Reversing this trend requires, apart from healthier lifestyles, improved diagnostic and prognostic tools. New and relevant protein biomarkers are essential components of these tools and therefore a pre-requisite for developing improved and personalized treatment. 

Proseek Multiplex CVD I 96x96 is a high throughput multiplex immunoassay which speedily allows analysis of 92 cardiovascular-related protein biomarkers across 96 samples simultaneously without any compromise in data quality. Only one microliter of sample is required, economizing on precious or biobanked clinical material. When used in conjunction with Fluidigm’s BioMark HD System, Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market today. Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time. Using the BioMark HD System with the Proseek Multiplex CVD I 96x96, a researcher can now obtain results for up to 9,216 reactions in just a few hours.

“It is a very exciting opportunity when Olink can offer a new tool for researchers, clinicians and anyone interested in cardiovascular diseases. It’s well known that all individuals are different and in an ideal world could receive personalized medicine and care. We would like to contribute to fulfilling that dream faster by helping to find new protein expression patterns that could serve as biomarkers” says Andrea Ballagi, Director Commercial Operations at Olink Bioscience.

The Proseek Multiplex CVD I 96x96 panel contains known cardiovascular and inflammatory markers as well as a few exploratory proteins which have great potential as new cardiovascular markers. The exploratory markers are intracellular proteins which were unexpectedly detected in serum or plasma samples, demonstrating that Proseek Multiplex is a sensitive tool for analyzing proteins in body fluids.

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach. The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level -- and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR.

“The cardiovascular panel has already attracted a lot of interest among cardiovascular researchers; we have many customers knocking on our door eager to start analyzing their own clinical samples. We have already performed some initial testing of the panel and the results look very promising. We are very excited about the possibilities Proseek Multiplex CVD I 96x96 offers to the cardiovascular research community and pharmaceutical industry” says Agneta Siegbahn, Professor in Clinical Coagulation Science, Department of Medical Sciences, Uppsala University and Managing Director of Clinical Biomarkers Facility at Science for Life Laboratory in Uppsala, Uppsala University, one of Olink’s service providers.

Proseek Multiplex is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

Proseek Multiplex CVD I 96x96 is the second panel from Olink. The company has launched the Proseek Multiplex Oncology I 96x96 product previously this year. Both are for research use only.

About Olink 

Olink Bioscience produces innovative products for biomarker research and development. Our goal is to help our customers and collaborators to improve clinical decisions through the use of molecular biomarkers. Our groundbreaking tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and industry with over 700 customer publications. Proseek Multiplex is a next generation multivariate protein biomarker detection kit. It allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 92 proteins in just 1 microliter liquid sample, such as serum and plasma, with exceptional analytical performance.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink AB and Proseek are trademarks or registered trademarks of Olink Bioscience.

Contact information
Andrea Ballagi, MD, PhD, MBA
Director Commercial Operations
Phone: +46-18-444 3970
E-mail: info@olink.com

Uppsala, Sweden, October 29, 2013 – Olink Bioscience today launches Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease. This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Read more »
Media-no-image

Fluidigm and Olink Bioscience Bring a New Level of Protein Biomarker Discovery to the Life Science Research Market - 96 Samples Across 92 Proteins in One Microfluidic Run

Press Releases   •   Jul 31, 2013 09:12 EDT

UPPSALA, Sweden and SOUTH SAN FRANCISCO, Calif., USA -- July 31, 2013 -- Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day.

The two companies will co-market the combination of their respective products --  Fluidigm’s BioMarkTM HD System and Olink Bioscience’s Proseek® Multiplex technology -- bringing protein research to the Fluidigm platform and Olink Bioscience’s protein detection assays to the high-throughput, high reproducibility and unparalleled sensitivity realm of Fluidigm’s real-time PCR system. 

Fluidigm’s BioMark HD System and Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market today.  Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time.  Using the BioMark HD System with the Proseek Multiplex Oncology I 96x96 Kit, a researcher can simultaneously analyze 96 human samples against a panel of 92 analytes, such as growth factors, inflammatory markers, soluble receptors, or cancer antigens. With the addition of four control analytes (two incubation controls, and extension and detection controls), researchers can now obtain results for up to 9,216 reactions in just a few hours. 

The first 92-plex Olink panel, available now, is focused on biomarker discovery for cancer. Panels addressing cardiovascular disease and inflammation are expected to be offered later this year.

“Protein research is so important because these biomarkers are used to monitor health states and predict treatment outcomes in patients. One of the biggest trends in the life sciences industry today is research to uncover biomarkers that can lead to companion diagnostics," said Simon Fredriksson, Olink Bioscience president and chief executive officer. “Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity when more and more assays are run simultaneously. Olink’s Proseek Multiplex generates high quality data even in highly multiplexed formats, and using these assays in conjunction with Fluidigm’s BioMark HD System gives protein researchers easy access to unprecedented volume and quality of data.” 

The Olink Bioscience assay provides a signal when pairs of antibodies equipped with DNA reporter molecules bind to their targets to create new DNA amplicons. The amplicons are subsequently quantified by high throughput real-time PCR. With PCR’s large dynamic range and superb sensitivity, in combination with Olink Bioscience’s unique protein detection assays, the opportunities are enormous for powerful analysis of multivariate biomarker patterns. 

“Analyzing 92 proteins from one microliter of sample enables new biomarker discovery and validation,” said Gajus Worthington, Fluidigm president and chief executive officer. “Many sample sources, including those from biorepositories or model organisms, are limited, and researchers can simply run out before they are able to find useful biomarker panels.  The combination of Fluidigm’s BioMark HD System and Olink’s Proseek Multiplex assay represents a robust new tool for the protein research community." 

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach. The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level -- and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR. 

Olink Bioscience's Proseek Multiplex is a multivariate protein biomarker detection kit based on Olink’s proprietary Proximity Extension Assay (PEA). It uniquely allows multiplexing of immunoassays without compromising assay performance. PEA uses pairs of oligonucleotide-labeled antibodies equipped with DNA reporter molecules to bind to proteins of interest in a highly specific manner, solving the antibody cross-reactivity dilemma that plagues and limits conventional protein assays. 

About Olink Bioscience
Olink Bioscience develops, manufactures, and markets unique and highly innovative proprietary products for biomarker research and development. Together with their customers and collaborators they aim to improve clinical decision making by the use of molecular biomarkers. Their groundbreaking tools gain new insights in disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In Situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and pharmaceutical industry with over 700 customer publications. Proseek Multiplex is a next generation multivariate protein biomarker detection kit. It uniquely allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 92 proteins in just 1 μL liquid samples, such as serum and plasma, with exceptional analytical performance.

Olink Bioscience is headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink AB and Proseek are trademarks or registered trademarks of Olink Bioscience. 

About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including 13 different commercial IFCs for nucleic acid analysis, and three families of assay chemistries. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm products are provided: For Research Use Only. Not for use in diagnostic procedures.

For more information, please visit www.fluidigm.com. 

Fluidigm, the Fluidigm logo, and BioMark are trademarks or registered trademarks of Fluidigm Corporation. 

Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Fluidigm’s product and marketing plans, development, objectives, expectations and/or strategies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, marketing, and selling products.  Information on these and additional risks affecting Fluidigm’s business and operating results are contained in its filings with the Securities and Exchange Commission, including its most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements.

Contact:
Howard High
Fellow, Corporate Communications and Press Relations
Fluidigm Corporation
650-266-6081 (office)
510-786-7378 (mobile)
howard.high@fluidigm.com

Simon Fredriksson, Ph.D. 
Olink AB 
Phone: +46 18 444 3970 
E-mail: info@olink.com

Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day. The two companies will co-market the combination of their respective products -- Fluidigm’s BioMarkTM HD System and Olink Bioscience’s Proseek® Multiplex technology.

Read more »
Media-no-image

A new European Consortium to boost our understanding of Inflammatory Bowel Diseases

Press Releases   •   May 17, 2013 08:21 EDT

The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation. The consortium associates 10 European partners from both academia and industry. It starts with a € 6M grant thanks to the European Commission´s 7th Framework Program (FP7*).

The project will generate the largest collection of samples so far assembled from treatment naïve patients recently diagnosed with inflammatory bowel disease.  DNA methylation and RNA transcription status, protein markers, gut microbial content, patient genotype for known susceptibility loci and classical clinical data will be extensively analyzed for the characterization of the cohort in order to create a molecular snapshot of IBD in its early manifestation. This massive molecular profiling will be used to yield a list of biomarkers indicative for onset of the disease.

The participating Small and Medium sized Enterprises (SMEs) will develop assays capable of analyzing panels of several hundred relevant protein markers as well as methods for rapid profiling of gut microbial content relevant for IBD. The proposed biomarkers will form a solid ground for development of improved diagnostic assays and be a rich source to mine for novel therapeutic targets.

"We are pleased to have gathered such a strong combination of clinicians, clinical researchers, basic researchers and innovative SME:s into one focused project," said Dr. Mats Gullberg, project coordinator for IBD-Character and Chief Technology Officer at Olink Bioscience. "The project will advance our understanding of IBD as well as generate proprietary products by the participating SMEs. The project will provide the most complete molecular characterization of samples from patients with IBD and also progress the field of analysis of large data sets containing different types of molecular markers from large sets of individuals."

Based on the findings within the IBD-Character project, results are expected to improve many aspects of patient care, including the development of new personalized medical strategies and treatments.

Consortium members

The project will be co-ordinated by Olink Bioscience (Sweden) with partners coming from several European countries including the United Kingdom, Sweden, Belgium, Spain and Norway. The IBD-Character Consortium unites researchers from three SME:s, one research institute, five Universities and one public, non-profit organization.

IBD-Character is a four year project running from the 1st of December 2012 until the 30th of November 2016 and is funded by the 7th Framework Program of the European Commission. In addition to the research activities, IBD-Character will be organizing meetings, workshops and will be present at a number of international conferences.

Members of the consortium:
• Olink Bioscience (Coordinator, SME), Mats Gullberg, SE
• Diagenode (SME), Hélène Pendeville, BE
• Genetic Analsysis (SME), Heidi Vebø, NO
• Instituto Aragonés de Ciencias de la Salud/IIS Aragón, Fernando Gomollón, ES
• Linköpings Universitet, Johan Söderholm, Åsa Keita SE
• The University of Edinburgh, Jack Satsangi, UK
• Örebro University Hospital, Jonas Halfvarson, SE
• Centro Nacional de Análisis Genómico, Ivo Gut, Monica Bayés, ES
• Karolinska Institutet, Mauro D’Amato, SE
• Universitetet I Oslo, Morten H. Vatn, Bettina Kulle Andreassen, NO

Contact:
Dr. Mats Gullberg (Project Coordinator)
Phone: +46-18-4443980
E-mail: Mats.Gullberg@olink.com
IBD-Character website: www.IBDcharacter.eu

* FP7 is the short name for the Seventh Framework Programme for Research and Technological Development. This is the EU's main instrument for funding research in Europe and it will run from 2007-2013.


The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance our understanding of the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease and to increase diagnostic precision in detection of the diseases in their early manifestation.

Read more »
Eco4eo7qngjvrk6ogrnt

Olink Bioscience Introduces Scalable Protein Biomarker Assays with Proseek Multiplex

Press Releases   •   Mar 12, 2013 08:57 EDT

Olink launches Proseek Multiplex – a new generation of multiplexed protein biomarker immunoassays. Until now, it has been impossible to scale up conventional assays due to increased antibody cross-reactivity when large numbers of assays are run simultaneously. With Proseek Multiplex, 92 proteins can be quantified in just one microliter sample without compromising data quality or performance.

Media-no-image

Olink Bioscience appoints Sigma-Aldrich as distributor of Duolink

Press Releases   •   Feb 12, 2013 08:44 EST

Uppsala, Sweden, February 12, 2013 – Olink Bioscience today announced the appointment of Sigma® Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, as distributor of the Duolink® In Situ product line in nearly all geographies worldwide for the research market. The agreement will expand the market for Duolink In Situ by leveraging the industry-leading marketing, sales, support and distribution power of Sigma® Life Science. Olink Bioscience will continue to develop the protein biomarker market.

“We believe our agreement will build awareness and develop the market for Duolink In Situ through the global sales and support organization that serves our growing customer base locally ”said Simon Fredriksson, CEO and President of Olink Bioscience. “The Sigma® Life Science product range for Cell Biology is extensive and a perfect context for customers interested in Duolink In Situ.”

“Duolink In Situ is a powerful addition to our portfolio of Proteomics products and will be readily
available through the sigma-aldrich.com website", said Josef Zihlmann, Vice President, Marketing, Sigma Life Science. "The ability to visualize protein-protein interactions in unmodified cells under endogenous expression is a fundamental advance, and can provide enhanced insight into basic biology, disease-relevant signaling pathways, and potential therapeutic compounds that can manipulate those pathways”.

About Olink AB

Olink Bioscience develops, manufactures, and markets unique and highly innovative proprietary products for biomarker research and discovery. Together with our customers and collaborators
we aim to improve clinical decision making by the use of molecular biomarkers. Our groundbreaking tools gain new insights in disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink In Situ product line enables detailed analyses of cell signaling
pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink is today used by a broad customer base worldwide in both academia and pharmaceutical industry. Proseek® is a next generation multivariate protein biomarker detection product. It uniquely allows multiplexing of immunoassays without compromising assay performance. Proseek simultaneously quantifies up to 96 proteins in just 1 μl liquid samples such as serum and plasma with exceptional analytical performance.

Olink’s patented molecular technologies are also commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink Bioscience is headquartered in Uppsala, Sweden.

 

For more information, please contact:

Simon Fredriksson, President and CEO, Olink AB

Phone: +46 18 444 3970

Mobile: +46 76 1169442

E-mail: Simon.Fredriksson@olink.com

 

Olink and Duolink are registered trademarks of Olink AB. Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC registered in the US and other countries.

 



Uppsala, Sweden, February 12, 2013 – Olink Bioscience today announced the appointment of Sigma® Life Science, the innovative biological products and services business unit of Sigma-Aldrich Corporation, as distributor of the Duolink® In Situ product line in nearly all geographies worldwide for the research market.

Read more »
Imachhiegwxtr0yuw5anw

Olink AB and Bethyl sign distribution agreement for the US market

Press Releases   •   Nov 21, 2011 09:00 EST

Olink Bioscience, a Sweden based biotechnology company focused on innovative protein detection technologies, has entered into a distribution agreement with Bethyl Laboratories, Inc. Together with Bethyl Olink Bioscience will continue to expand the distribution of the Duolink® product line in the US market.

Media-no-image

Olink Appoints New CEO and Expands Board of Directors

Press Releases   •   Sep 14, 2011 09:32 EDT

UPPSALA, Sweden, 14 September 2011 – Dr. Simon Fredriksson, Executive Vice President and Chief Scientific Officer of Olink AB (Olink) has today been promoted to President and CEO of Olink. Simon Fredriksson is taking over from Björn Ekström who has been managing the company since its inception in 2004. At the same time new members of the Board of Directors have been appointed. These changes follow the purchase by Nexttobe AB (nxt2b) of a significant part of the shares in Olink as announced last week, and it is a first step to accelerate the development of Olink. 

“I am very happy to hand over management of Olink to Simon. We have been working side by side for several years and it is with great pleasure I have seen him rapidly develop into a very competent leader and businessman. With his excellent technical and scientific background combined with his eagerness to expand sales and his market insights he is a perfect successor now that I have decided to step down”, says Björn Ekström, retiring President and CEO of Olink and new member of the Olink Board of Directors.

“It is a great honor for me to be entrusted to lead Olink forward in this phase of rapid development. With a strong product portfolio and an exciting pipeline of new business opportunities I am looking forward to realizing the full potential of Olink”, says Simon Fredriksson.

New members of the Board of Directors have also been appointed, and Bengt Ågerup will be the Chairman of the Board. The other members are Olle Kämpe, Håkan Englund, Björn Ekström, Ulf Landegren and Mats Nilsson together forming a strong board with a vast competence and experience from science and technology to rapid sales growth, innovative marketing and global business.

Bengt  Ågerup is a PhD and has held senior positions within Pharmacia and Biomatrix, and he started the company Q-Med that was subsequently sold to Galderma in 2011. Bengt is the founder of nxt2b, Chairman of Stockholm Uppsala Life Science, and a Board Member of the Swedish Foundation for Strategic Research.

Ulf Landegren is Professor of Molecular Medicine at Uppsala University. He is co-founder of Olink, and he was PhD supervisor of the other academic founders. He is a fellow of the Royal Swedish Academy of Sciences, member of the European Molecular Biology Organization, fellow of School of Engineering at Tokyo University, and he sits on scientific advisory boards of several companies and research organizations. He is the inventor of 32 patents or applications.

Olle Kämpe is Professor of Molecular Medicine at Uppsala University since 1999 and senior consultant in internal medicine and in endocrinology at the University Hospital in Uppsala.  He is a fellow of the Royal Swedish Academy of Sciences, appointed by the Swedish Research Council to the board of the Swedish Infrastructure for large scale sequencing (SNISS) and scientific adviser part-time to nxt2b.

Håkan Englund has more than 30 years of experience from the life science industry and has held several leading positions at Pharmacia Biotech (currently GE HealthCare) and Phadia. At Phadia he has been responsible for commercialization of new business and product areas such as POC and multiplexing within allergy diagnostics. He is presently board member of Uppsala Bio and Uppsala Chamber of Commerce.

Björn Ekström is co-founder and retiring President and CEO of Olink. He was co-founder and Executive VP of Pyrosequencing AB and part of the IPO team listing the company on Stockholm Stock Exchange in 2000. Prior to that he held several leading positions within Pharmacia Biotech (currently GE HealthCare). Ekström serves on the board of Cobolt AB, Qlinea AB, Sigolis AB, and Halo Genomics AB.

Mats Nilsson is co-founder and has been member of the board since inception. He is professor of Molecular Diagnostics at Uppsala University where he heads a research group developing new analytical tools for research and diagnostics. He has co-founded four biotech start-up companies and is currently on the board of Halo Genomics AB, ELOS AB, and chairs the board of Q-linea AB.

About Olink AB
Olink Bioscience, a company founded by scientists at Uppsala University, is commercializing cutting-edge technologies for analysis of proteins and nucleic acids revealing new insights into basic science, drug development, and diagnostics.  Our products are available worldwide through a network of distributors and through our web shop. The Duolink® product line enables users to visualize and quantify individual proteins, their interactions and modifications, in unmodified cells and tissues. Proseek® is an open assay development reagent kit for analyzing proteins in only 1 µl of serum or plasma sample with high sensitivity.

Olink’s molecular technologies are also commercialized through partnerships with industry leading organizations such as Affymetrix, Life Technologies, and through Olink spin-out companies Halo Genomics and Qlinea. Olink Bioscience was founded in 2004 and is headquartered in Uppsala, Sweden

For more information, please contact
Simon Fredriksson, President and CEO, Olink AB
Phone: +46 18 444 3970
Mobile: +46 76 1169442

 

 

 

UPPSALA, Sweden, 14 September 2011 – Dr. Simon Fredriksson, Executive Vice President and Chief Scientific Officer of Olink AB (Olink) has today been promoted to President and CEO of Olink. Simon Fredriksson is taking over from Björn Ekström who has been managing the company since its inception in 2004. At the same time new members of the Board of Directors have been appointed.

Read more »
G4tqs1ejo28mka58ayuw

nxt2b becomes a major shareholder in Olink AB

Press Releases   •   Aug 29, 2011 08:20 EDT

nxt2b (Nexttobe AB) an investment company owned by Bengt Ågerup, has today signed an agreement with a group of shareholders in Olink AB to purchase 49 % of the outstanding shares in the company. The intention is to accelerate the growth and value creation of the company by injecting knowledge, experience and financial strength to complement Olink’s unique product and technology position.

S67kn3zehikc88rdurxfzg

Olink Bioscience appoints Simon Fredriksson Ph.D. as Executive Vice President

Press Releases   •   Jun 15, 2011 03:41 EDT

Simon Fredriksson co-founder and CSO of Olink AB has today been promoted to executive Vice President. With the new appointment follow increased responsibilities for global business development and external research collaborations.

Contacts 3 contacts

  • Press Contact
  • Marketing Coordinator
  • Marketing Communication

About Olink Bioscience

Olink Bioscience develops, manufactures, and markets unique and highly innovative proprietary products for biomarker research and discovery.

Olink Bioscience develops, manufactures, and markets unique and highly innovative proprietary products for biomarker research and discovery. Together with our customers and collaborators we aim to improve clinical decision making by the use of molecular biomarkers. Our groundbreaking tools gain new insights in disease processes, improve disease detection, and contribute to a better understanding of biology. The Duolink® In Situ product line enables detailed analyses of cell signaling pathways by microscopic visualization and quantification of endogenous protein interactions and modifications. Duolink In Situ is today used by a broad customer base worldwide in both academia and pharmaceutical industry. Proseek® Multiplex is a next generation multivariate protein biomarker detection product. It uniquely allows multiplexing of immunoassays without compromising assay performance. Proseek Multiplex simultaneously quantifies up to 96 proteins in just 1 μl liquid samples such as serum and plasma with exceptional analytical performance.
Olink’s patented molecular technologies are also commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink Bioscience is headquartered in Uppsala, Sweden.

Address

  • Olink Bioscience
  • Dag Hammarskjölds väg 52 B
  • 752 37 Uppsala
  • Our homepage

Links